Mendel vs Idexx Laboratories
Side-by-side comparison of AI visibility scores, market position, and capabilities
Clinical trial AI platform extracting structured insights from unstructured medical records; NLP for patient eligibility matching, pharmacovigilance, and real-world evidence generation.
About
Mendel is a clinical trial data management and AI platform that accelerates pharmaceutical and biotech drug development by extracting structured insights from unstructured medical records — physician notes, pathology reports, lab results, and clinical documentation — using natural language processing to identify patients eligible for trials, adverse events, and endpoint assessments. Founded in 2017 and headquartered in San Francisco, Mendel raised approximately $35 million and serves life sciences companies, hospital systems, and CROs (contract research organizations) running clinical trials.
Veterinary diagnostics leader with $3.81B FY2024 revenue; 130,000+ analyzer installed base; AI-powered inVue Dx digital cytology; VetConnect data platform; pet humanization tailwind.
About
IDEXX Laboratories is the global leader in veterinary diagnostics and information technology for companion animal healthcare, founded in 1983 by David Shaw in Westbrook, Maine, where it remains headquartered. The company trades on Nasdaq (IDXX) and reported $3.81 billion in revenues for FY2024, maintaining its dominant position in point-of-care veterinary diagnostics through an installed base of over 130,000 Catalyst chemistry analyzers, ProCyte hematology systems, and SNAP rapid assay devices deployed in veterinary clinics worldwide. CEO Jay Mazelsky has continued IDEXX's expansion into AI-powered diagnostics and digital pathology, building on over four decades of veterinary-specific product development.
AI Visibility Head-to-Head
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.